Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
The news feed for INNOVENT BIOLGCS UNSP/ADR (IVBIY) aggregates company press releases and media updates from Innovent Biologics, Inc., a biopharmaceutical company focused on oncology, cardiovascular and metabolic, autoimmune and ophthalmology diseases. These announcements provide insight into clinical trial progress, regulatory milestones, product approvals and corporate strategy that can influence how investors and observers view IVBIY.
Recent news highlights include multiple updates on mazdutide, a dual GCG/GLP-1 receptor agonist licensed from Eli Lilly for development in China. Innovent has reported National Medical Products Administration approvals for mazdutide in chronic weight management for adults with overweight or obesity and for glycemic control in adults with type 2 diabetes, along with Phase 3 data from the GLORY and DREAMS clinical programs. Other cardiovascular and metabolic pipeline news covers tigulixostat, a xanthine oxidase inhibitor for gout, and IBI3032, an oral GLP-1 receptor agonist with U.S. FDA IND approval for Phase 1 trials.
Oncology news items describe the development of IBI363, a PD-1/IL-2α-bias fusion protein, including U.S. FDA clearance of an IND for a global Phase 3 trial in immunotherapy-resistant squamous non-small cell lung cancer and data presented at major oncology conferences. Additional coverage includes IBI343, an anti-CLDN18.2 ADC with Phase 1 results in gastric/gastroesophageal junction adenocarcinoma published in Nature Medicine and the launch of multi-regional Phase 3 studies.
Investors following IVBIY can use this page to review updates on Innovent’s broader pipeline, such as picankibart for psoriasis, IBI324 for retinal diseases, and other marketed products mentioned in interim results and R&D day communications. Bookmark this news section to monitor how clinical data releases, regulatory decisions and partnership announcements may shape the company’s long-term development and commercialization plans.
Innovent Biologics (IVBIY) hosted its Oncology R&D Day, unveiling its strategic focus on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. The event, which attracted over 500 participants, showcased the company's ambitious plans to advance at least five pipeline assets into MRCT Phase 3 by 2030.
The company highlighted its flagship product IBI363, a first-in-class PD-1/IL-2α-bias fusion protein, which demonstrated breakthrough potential in three hard-to-treat tumors with significant survival benefits: median overall survival up to 17.5 months in NSCLC, 16.1 months in later-line CRC, and 14.7 months in immune-resistant melanoma. IBI363 has received two Breakthrough Therapy Designations from NMPA CDE and two Fast Track Designations from FDA.
Innovent's pipeline includes nearly 10 next-generation molecules in global development, supported by R&D hubs in Shanghai and San Francisco, with antibody and ADC manufacturing capacity exceeding 140,000L. Key candidates include IBI343 (CLDN18.2 ADC), IBI3009 (DLL3 ADC), IBI3003 (tri-specific T-cell engager), IBI3001 (EGFR/B7H3 ADC), and IBI3020 (CEACAM5 dual-payload ADC).
Innovent Biologics (IVBIY) has received approval from China's NMPA for mazdutide, the world's first dual GCG/GLP-1 receptor agonist for chronic weight management in Chinese adults with overweight or obesity.
The approval is based on the GLORY-1 Phase 3 study, which demonstrated significant results at week 48: 14.8% mean body weight reduction with 6mg dose, 82.8% of participants achieving ≥5% weight loss, and 50.6% achieving ≥15% weight loss. The drug also showed impressive liver fat content reduction of up to 80.24% in the 6mg group.
This approval addresses a critical healthcare need in China, where over 500 million adults live with overweight or obesity, costing the country approximately $283.3 billion in GDP loss in 2020.
Innovent Biologics (IVBIY) presented Phase 3 clinical study results (DREAMS-1) for mazdutide, their dual GCG/GLP-1 receptor agonist, at the ADA 85th Scientific Sessions. The study, involving 319 Chinese patients with type 2 diabetes, demonstrated significant efficacy with HbA1c reduction of 2.15% and body weight reduction of up to 7.81% after 24 weeks of treatment.
The trial met its primary and secondary endpoints, showing superior results compared to placebo. 87.4% of participants receiving mazdutide 6 mg achieved HbA1c <7.0%. The drug also showed improvements in cardiometabolic risk factors with a favorable safety profile. Two NDAs for mazdutide are currently under review by China's NMPA for chronic weight management and glycemic control.